Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03169231 · ClinicalTrials.gov registry record · Phase 2
Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty
A Phase 2 study, sponsored by Longeveron.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT03169231 is a Phase 2 study that has completed, run by Longeveron. The registered enrollment target is 150 participants.
The verdict
NCT03169231, a Phase 2 study, has completed, sponsored by Longeveron.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
This is a randomized, placebo-controlled, double-blind, parallel arm, multi-center Phase 2b study.
Interventions
- OTHER Placebo
- BIOLOGICAL Longeveron Mesenchymal Stem Cells (LMSCs)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2017-07-06 |
| Est. Completion | 2021-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03169231
The ClinicalTrials.gov registry entry for NCT03169231 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Longeveron, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03169231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03169231 about?
NCT03169231 is a clinical study titled "Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty". This is a randomized, placebo-controlled, double-blind, parallel arm, multi-center Phase 2b study.
What is the current status of trial NCT03169231?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2017-07-06. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT03169231?
The interventions under investigation include: Placebo (OTHER), Longeveron Mesenchymal Stem Cells (LMSCs) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03169231?
This trial is sponsored by Longeveron, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.